Underactivity of A/-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission may play a critical role in schizophrenia (SZ) and, in particular, may underlie persistent negative symptoms and cognitive dysfunction. NMDA receptors are regulated in vivo by the amino acids glycine and D-serine, which bind to a modulatory site on the NMDA receptor complex. Studies using full agonists (glycine and D~serine) and a partial agonist (D-cycloserine) of the NMDA receptor added to conventional or atypical antipsychotics have yielded encouraging, but mixed, results due in part to limitations in the pharamacokinetic/pharmacodynamic properties of the compounds themselves. An alternative approach to raising brain glycine levels is administering compounds that block synaptic glycine reuptake in brain via glycine (GLYT1) transporters. GLYT1 transporters are co-localized with NMDA receptors in the brain and function to limit glycine levels in the immediate vicinity of NMDA receptors. Glycine transport inhibitors have proven effective in numerous animal models of SZ. Although high-affinity glycine transport inhibitors have been developed by several pharmaceutical companies, clinical data are, as yet, unavailable. Sarcosine (A/-methylglycine) is a naturally occurring glycine type I (GLYT1) transport inhibitor that has been reported to improve negative symptoms and cognition in both chronic and acutely decompensated patients in studies conducted in Taiwan, but remains unavailable in the US. In this project, we will perform a randomized, placebo-controlled study of sarcosine as add-on treatment to anti-psychotics in first episode schizophrenia patients in Israel. Use of sarcosine has been approved in Israel based upon the successful clinical trials that were conducted in Taiwan. Studies in Israel will be conducted in accordance with FDA GCP and GLP guidelines and will be supported by Data Management/Biostatistic core (Core C). Neurophysiological outcome measures will be incorporated into the study and will be supported by the Patient Assessment/Recruitment core (Core B). The study will also take advantage of the Israeli Draft Board Registry, which provides objective premorbid data on participating subjects. It is hypothesized that impaired premorbid function will predict more severe neurocognitive and neurophysiological deficit, and greater benefit from an NMDA-based approach.

Public Health Relevance

Schizophrenia is a major mental disorder. Neurocognitive dysfunction is a core component of schizophrenia and a major determinant of poor long-term outcome. This project is part of a Center application to determine brain mechanisms underlying neurocognitive dysfunction in schizophrenia with particular emphasis on sensory processing dysfunction. This project will evaluate the effects of the glycine transport inhibitor sarcosine on persistent neurocognitive deficits in schizophrenia. If successful, it will support a new treatment approach for schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
5P50MH086385-05
Application #
8502376
Study Section
Special Emphasis Panel (ZMH1-ERB-F)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2013
Total Cost
$153,789
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Ding, Yulong; Martinez, Antigona; Qu, Zhe et al. (2014) Earliest stages of visual cortical processing are not modified by attentional load. Hum Brain Mapp 35:3008-24
Brunoni, Andre R; Shiozawa, Pedro; Truong, Dennis et al. (2014) Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis. Expert Rev Med Devices 11:383-94
Pitts, Michael A; Padwal, Jennifer; Fennelly, Daniel et al. (2014) Gamma band activity and the P3 reflect post-perceptual processes, not visual awareness. Neuroimage 101:337-50
Merkel, Christian; Stoppel, Christian M; Hillyard, Steven A et al. (2014) Spatio-temporal patterns of brain activity distinguish strategies of multiple-object tracking. J Cogn Neurosci 26:28-40
Revheim, Nadine; Corcoran, Cheryl M; Dias, Elisa et al. (2014) Reading deficits in schizophrenia and individuals at high clinical risk: relationship to sensory function, course of illness, and psychosocial outcome. Am J Psychiatry 171:949-59
Schoenfeld, Mircea A; Hopf, Jens-Max; Merkel, Christian et al. (2014) Object-based attention involves the sequential activation of feature-specific cortical modules. Nat Neurosci 17:619-24
Gill, Kelly Elizabeth; Evans, Elizabeth; Kayser, Jürgen et al. (2014) Smell identification in individuals at clinical high risk for schizophrenia. Psychiatry Res 220:201-4
Feng, Wenfeng; Störmer, Viola S; Martinez, Antigona et al. (2014) Sounds activate visual cortex and improve visual discrimination. J Neurosci 34:9817-24
Hoptman, Matthew J; Antonius, Daniel; Mauro, Cristina J et al. (2014) Cortical thinning, functional connectivity, and mood-related impulsivity in schizophrenia: relationship to aggressive attitudes and behavior. Am J Psychiatry 171:939-48
Kantrowitz, J T; Hoptman, M J; Leitman, D I et al. (2014) The 5% difference: early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder. Psychol Med 44:25-36

Showing the most recent 10 out of 47 publications